Navigation Links
Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
Date:8/5/2008

$(1.64) $(1.18)

Shares used in calculating net

loss per share allocable

to common stockholders,

basic and diluted 73,815 60,914 73,710 60,825

Arena Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheet Data

(In thousands)

June 30, December 31,

2008 2007

(unaudited) (Note)

Assets

Cash, cash equivalents and short-term

investments $272,160 $398,185

Accounts receivable 2,523 1,901

Other current assets 8,586 9,162

Land, property and equipment, net 98,312 65,940

Acquired technology and other non-current

assets 25,653 12,318

Total assets $407,234 $487,506

Liabilities and Stockholders' Equity

Accounts payable, accrued expenses and

accrued compensation $44,210 $30,058

Total deferred revenues 4,049 4,049

Total lease financing obligations and

other long-term liabilities 72,782 63,100

Redeemable convertible preferred stock 55,009 53,922

Total stockholders' equity 231,184 336,377

Total liabilities and stockholders'

equity $407,234 $487,506

Note: The Condensed Consolidated Balance Sheet Data has been derived from the audited financial statements as of that date.

Contacts: Jack Lief
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
2. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
3. ThreeWire Expands Presence in the Pharmaceutical Arena
4. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
5. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
6. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
8. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 21, 2015 Cambridge Semantics, the leading provider ... announced that 2014 was a record-breaking year across the board ... the Anzo Smart Data Platform and our Smart Data solutions, ... from diverse data which led to record growth for the ...
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Pipette.com ... Offer to their comprehensive portfolio of Eppendorf products. ... customers to purchase a Centrifuge 5424/5424 R and receive ... of either Eppendorf Research plus or Eppendorf Reference 2 ...
(Date:1/22/2015)... Geneva, Switzerland (PRWEB) January 22, 2015 ... for characterized mammalian Research Cell Banks (RCBs) used for ... generated Research Cell Banks will include Next-Generation Sequencing ... cell’s genetic architecture de-risks biologic manufacturing by ensuring the ...
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... PALO ALTO, Calif., Oct. 24 Vivo Ventures, a ... that,James Huang will join the firm as an Executive ... Mr. Huang will,work with Vivo,s portfolio companies while enhancing ... James coming on board and what he will be ...
... 24 Cell Therapeutics,Inc. (CTI) (Nasdaq and ... 19th annual AACR-NCI-EORTC Symposium show its bis-platinate ... to currently,marketed platinum agents carboplatin, cisplatin and ... in late 2008. "Bis-platinates represent a ...
... is available in German . , Hydrogen fuel ... have so far suffered from being insufficiently competitive. At the ... Strasser has now developed a new class of electrocatalyst that ... active phase of the catalyst consists of nanoparticles with a ...
Cached Biology Technology:Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 3Platinum-rich shell, platinum-poor core 2
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... 2015  BellBrook Labs, a leader in high throughput ... of a TR-FRET (time resolved Forster resonance energy ... a high throughput screening assay for glycosyltransferases and ... for sensitive detection of hundreds of human and ...
(Date:1/22/2015)... Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication company ... of the Wocket™ smart wallet at CES 2015 in Las ... one of the "11 Hot Products at CES" in a review published ... Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... turfgrass has become increasingly restricted due to environmental ... and industrial consumption; and contamination of potable water ... need to identify promising water conservation strategies and ... In their ongoing search for ways to improve ...
... Washington, D.C. -- Disease statistics buried within patient ... and organized to depict geographic patterns, allowing the discovery ... Penn State geographer. "The use of interactive maps ... to greater insight into complex events like the spread ...
... The ELCC Press Program will feature new study ... (embargoed to time of their presentation at ELCC): ... Pemetrexed plus cisplatin with radiation in patients with locally ... therapeutic combination, Screening for lung cancer in organ transplant ...
Cached Biology News:Common PGR helps creeping bentgrass weather drought 2Visualization of geographic patterns may predict spread of disease 22nd European Lung Cancer Conference 22nd European Lung Cancer Conference 3
VEGF Receptor-2, phospho-specific (Tyr996)...
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
IC50: 35 ng/ml · Limit of detection: 8 ng/ml...
Biology Products: